Most of what time? The patent just expired a few months ago. Generics are now ramping up because the patent expired, not because of some hypothetical eight year clinical trials. And for that matter, generics of existing ingredients and dosages do not have to repeat clinical trials anyways, which is one of the big reasons generics are a lot less expensive.
This hypothesis seems retconned and completely at odds with the actual facts. Not least that there has been absolutely nothing exceptional about the pricing of their product in Canada, which has always been one of the cheaper pricings worldwide.
This article is saying that the patent elapsed in 2018 because thy didn’t pay the $250 to renew the patent. Instead they relied on “data exclusivity” which means their trial data is exclusively theirs and anyone who wants to sell in Canada must first run safety trials of their own at a huge expense. It’s just as good as a patent but has a shorter window of exclusivity.
> Instead they relied on “data exclusivity” which means their trial data is exclusively theirs and anyone who wants to sell in Canada must first run safety trials of their own at a huge expense.
Most of what time? The patent just expired a few months ago. Generics are now ramping up because the patent expired, not because of some hypothetical eight year clinical trials. And for that matter, generics of existing ingredients and dosages do not have to repeat clinical trials anyways, which is one of the big reasons generics are a lot less expensive.
This hypothesis seems retconned and completely at odds with the actual facts. Not least that there has been absolutely nothing exceptional about the pricing of their product in Canada, which has always been one of the cheaper pricings worldwide.